Page 9 - 81_03

Carmen Avendaño

28. Apolloni A, Hooker CW, Mak J, Harrich D. Human
Immunodeficiency Virus Type 1 Protease Regulation
of Tat Activity Is Essential for Efficient Reverse
Transcription and Replication. J Virol 2003; 77: 9912-
21.

29. Laird GM, Bullen CK, Rosenbloom DIS, et al. Ex vivo
analysis identifies effective HIV-1 latency–reversing
drug combinations. J Clin Invest 2015.
doi:10.1172/JCI80142.

30. Nagarajan S, Hossan T, Alawi M, et al. Bromodomain
Protein BRD4 Is Required for Estrogen Receptor-
Dependent Enhancer Activation and Gene
Transcription. Cell Rep 2014; DOI:
http://dx.doi.org/10.1016.

31. a) Picaud S, Wells C, Felletar I, et al. RVX-208, an
inhibitor of BET transcriptional regulators with
selectivity for the second bromodomain. Proc Natl
Acad Sci USA 2013; 110: 19754-9. b) McLure KG,
Gesner EM, Tsujikawa L, et al. RVX-208, an inducer
of ApoA-I in humans, is a BET bromodomain
antagonist. PLoS One 2013; 8:e83190.

32. Dawson MA, Kouzarides T, Huntly BJ. Targeting
epigenetic readers in cancer. N Engl J Med 2012;
367:647-57.

33. Dhillon H, Chikara S, Reindl KM. Piperlongumine
induces pancreatic cancer cell death by enhancing
reactive oxygen species and DNA damage.
Toxicology Reports 2014; 1: 309-18.

34. a) Sharma SK, Ramsey TM, Blair KW. Protein-protein
interactions: lessons learned. Curr Med Chem Anti-
Cancer Agents 2002; 2: 311-30. b) Philpott M, Rogers
CM, Yapp C, et al. Assessing cellular efficacy of
bromodomain inhibitors using fluorescence recovery
after photobleaching. Epigenetics & Chromatin 2014;
7: 14.

220 @Real Academia Nacional de Farmacia. Spain